| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Amryt Pharma plc (NASDAQ: AMYT)
AMYT Technical Analysis
5
| As on 21st Apr 2023 AMYT STOCK Price closed @ 14.70 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 8.50 & Strong Buy for SHORT-TERM with Stoploss of 10.42 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AMYTSTOCK Price
| Open | 14.70 | Change | Price | % |
| High | 14.70 | 1 Day | 0.00 | 0.00 |
| Low | 14.70 | 1 Week | 0.00 | 0.00 |
| Close | 14.70 | 1 Month | 0.13 | 0.89 |
| Volume | N/A | 1 Year | 3.58 | 32.19 |
| 52 Week High 14.77 | 52 Week Low 6.30 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| HCTI | 0.03 | 0.00% |
| NVDA | 147.90 | 2.59% |
| GNLN | 0.01 | 0.00% |
| INTC | 22.55 | 6.42% |
| LMDX | 0.02 | 0.00% |
| PSTV | 0.19 | 5.56% |
| TSLA | 340.47 | -2.35% |
| INM | 3.87 | 57.96% |
| LCID | 2.17 | 0.46% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| AMYT Daily Charts |
AMYT Intraday Charts |
Whats New @ Bazaartrend |
AMYT Free Analysis |
|
|
AMYT Important Levels Intraday
| RESISTANCE | 14.70 |
| RESISTANCE | 14.70 |
| RESISTANCE | 14.70 |
| RESISTANCE | 14.70 |
| RESISTANCE | 14.70 |
| RESISTANCE | 14.70 |
| RESISTANCE | 14.70 |
| RESISTANCE | 14.70 |
AMYT Forecast June 2025
| 4th UP Forecast | 19.44 |
| 3rd UP Forecast | 17.92 |
| 2nd UP Forecast | 16.98 |
| 1st UP Forecast | 16.04 |
| 1st DOWN Forecast | 13.36 |
| 2nd DOWN Forecast | 12.42 |
| 3rd DOWN Forecast | 11.48 |
| 4th DOWN Forecast | 9.96 |
AMYT Weekly Forecast
| 4th UP Forecast | 17.21 |
| 3rd UP Forecast | 16.40 |
| 2nd UP Forecast | 15.91 |
| 1st UP Forecast | 15.41 |
| 1st DOWN Forecast | 13.99 |
| 2nd DOWN Forecast | 13.49 |
| 3rd DOWN Forecast | 13.00 |
| 4th DOWN Forecast | 12.19 |
AMYT Forecast2025
| 4th UP Forecast | 32.35 |
| 3rd UP Forecast | 26.69 |
| 2nd UP Forecast | 23.19 |
| 1st UP Forecast | 19.69 |
| 1st DOWN Forecast | 9.71 |
| 2nd DOWN Forecast | 6.21 |
| 3rd DOWN Forecast | 2.71 |
| 4th DOWN Forecast | -2.95 |
Amryt Pharma plc ( NASDAQ USA Symbol : AMYT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AMYT Business Profile
Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland. Address: 45 Mespil Road, Dublin, Ireland, 4
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service